Advice
Following SMC collaboration with NICE on MTA TA878: casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19:
tocilizumab (RoActemra®) is accepted for use within NHSScotland.
Indication under review: Treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice249KB (PDF)
Medicine details
- Medicine name:
- tocilizumab (RoActemra)
- SMC ID:
- SMC2552
- Indication:
Treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.
- Pharmaceutical company
- Roche
- BNF chapter
- Infections
- Submission type
- Collaboration
- Status
- Accepted
- Date advice published
- 29 March 2023